Elanco Animal Health Inc
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Elanco Animal Health completed a $120 million expansion of its biologics plant in Kansas, increasing capacity fourfold. The company plans to invest an additional $30 million by 2028, aiming for unconstrained supply of its dermatology product Befrena by early 2027, as demand is twice expectations.
Elanco Animal Health (NYSE: ELAN) will release its Q3 2026 financial results on November 6, 2026, followed by a conference call at 8:00 a.m. ET. The call will be webcast live and a replay will be available later. Elanco is a global animal health company focused on products for farm animals and pets.
Elanco Animal Health completed a $120M expansion of its Kansas biologics plant, increasing production capacity 4x. The site now serves as the company's center for monoclonal antibody (mAb) manufacturing, with plans for an additional $30M investment by 2028. Elanco acquired the site in 2021 and has since grown its workforce from 30 to over 200 employees. The expansion supports products like Trutect and Befrena, with demand for the latter exceeding expectations.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ELAN (Elanco Animal Health Inc). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent ELAN coverage spans financial news, corporate actions and technology.
In the last 30 days, ELAN insiders filed 2 SEC Form 4 transactions — 2 purchases ($1.0M) and no sales. The most active reporter was Kurzius Lawrence Erik with 1 filing.
The expansion significantly boosts Elanco's biologics manufacturing capability, supporting higher demand for its dermatology product Befrena.
The announcement sets a clear timeline for investors to prepare for the upcoming earnings, potentially increasing pre‑earnings positioning activity.
The expansion enhances supply reliability for Elanco's monoclonal antibody products, potentially supporting revenue growth in the animal health segment.
The new capacity could boost future revenue from monoclonal antibody products but also raises operating and capital intensity, pressuring margins if demand lags.
Regulatory approval opens new market for Elanco's pet health products.
AlphAI scores every news story that mentions ELAN with an AI model for sentiment and relevance, and aggregates insider trades from Elanco Animal Health Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Elanco Animal Health completed a $120 million expansion of its biologics plant in Kansas, increasing capacity fourfold. The company plans to invest an additional $30 million by 2028, aiming for unconstrained supply of its dermatology product Befrena by early 2027, as demand is twice expectations.
1 min readElanco Animal Health (NYSE: ELAN) will release its Q3 2026 financial results on November 6, 2026, followed by a conference call at 8:00 a.m. ET. The call will be webcast live and a replay will be available later. Elanco is a global animal health company focused on products for farm animals and pets.
1 min readElanco Animal Health completed a $120M expansion of its Kansas biologics plant, increasing production capacity 4x. The site now serves as the company's center for monoclonal antibody (mAb) manufacturing, with plans for an additional $30M investment by 2028. Elanco acquired the site in 2021 and has since grown its workforce from 30 to over 200 employees. The expansion supports products like Trutect and Befrena, with demand for the latter exceeding expectations.
2 min readElanco Animal Health completed a $150M expansion in Kansas, boosting monoclonal antibody production for products like Befrena and Trutect. The expansion supports revenue growth and future therapy development but also introduces risks related to higher operating costs. Elanco projects $5.8B revenue and $297.2M earnings by 2029, with analysts offering varied outlooks on its future performance.
3 min readThe FDA approved Capstar (Elanco) and nitenpyram (Felix) for preventing and treating New World screwworm in pets. The drugs are for dogs, cats, and kittens over 4 weeks old. 48 cases confirmed in the U.S. according to the USDA. Elanco and Felix are the manufacturers.
2 min readElanco Animal Health (ELAN) completed a 25,000-square-foot expansion of its Elwood, Kansas facility, boosting monoclonal antibody production. The $120M investment, with an additional $30M planned by 2028, supports demand for products like Befrena and Trutect. Elanco aims to meet growing pet health priorities and scale innovation.
4 min readElanco Animal Health completed a 25,000-square-foot expansion at its Elwood facility, increasing production capacity fourfold and adding 70 new jobs. The $150 million investment, planned through 2028, includes a new pilot plant and lab. Elanco manufactures USDA-approved treatments for pets at the site.
2 min readElanco Animal Health completed a $120 million expansion of its Elwood facility, adding 25,000 square feet and increasing production capacity for monoclonal antibodies. The expansion is expected to support the development of next-generation animal health treatments. Company and government officials celebrated the completion.
1 min readElanco Animal Health completed a $120M expansion in Kansas, quadrupling monoclonal antibody capacity. The expansion supports launches of Befrena and Trutect, key to Elanco's pet therapeutics strategy. The company projects $5.8B revenue and $297.2M earnings by 2029, with a 24% upside to its current price.
2 min readElanco Animal Health (ELAN) completed a 25,000-square-foot expansion to boost biologics production, including monoclonal antibody therapies. The company's P/S ratio is 2.51, slightly above its historical median, with a GF Score of 68. Insiders have purchased $2.6M in shares over the past year. GF Value™ estimates ELAN is 50.5% overvalued at $25.09 per share.
2 min read
